Journal
FUTURE ONCOLOGY
Volume 18, Issue 5, Pages 519-522Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2021-1309
Keywords
immunotherapy; ipilimumab; nivolumab; pembrolizumab; renal cell carcinoma; tyrosine kinase inhibitor
Categories
Ask authors/readers for more resources
The optimal sequencing and combination of ICIs to enhance oncologic outcomes for these patients remains a million-dollar question, as it is challenging to strike a delicate balance between utilizing the right window of opportunity to cure the disease and jeopardizing proven therapies for metastatic disease.
The million-dollar question remains the optimal sequencing and combination of ICIs to optimize oncologic outcomes for these patients. The big challenge lies in defining the thin line between utilizing the right window of opportunity to cure disease and jeopardizing proven therapies for metastatic disease
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available